The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE)

Theranostics

Volumn 4, Issue 7, 2014, Pages 736-744

  Ma, Wenhui ^a   Jia, Jia ^a   Wang, Shengjun ^a   Bai, Wei ^a   Yi, Jingwei ^a   Bai, Ming ^a   Quan, Zhiyong ^a   Yin, Zhanxin ^a   Fan, Daiming ^a   Wang, Jing ^a   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Computed tomography (CT); Hepatocellular carcinoma; Positron emission tomography (PET); Transarterial chemoembolization (TACE)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINATED POPPYSEED OIL; PIRARUBICIN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CATHETER; CHILD PUGH SCORE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVALUATION STUDY; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SCINTISCANNING;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902459028     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8725     Document Type: Article

References (24)

1. Trevisani F, De Notariis S, Rossi C, Bernardi M. Randomized control trials onchemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 2001;32:383-9.
2. Llovet JM, Bruix J. Systematic review of randomized trials for unresectablehepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42.
3. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88.
4. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomizedcontrolled trial of transarterial lipiodol chemoembolization for unresectablehepatocellular carcinoma. Hepatology 2002;35:1164-71.
5. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J. Arterial embolisation or chemoembolisationversus symptomatic treatment in patients with unresectable hepatocellularcarcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
6. EASL-EORTC clinical practice guidelines: management of hepatocellularcarcinoma. J Hepatol 2012;56:908-43.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
8. Shim JH, Lee HC, Kim SO, Shin YM, Kim KM, Lim YS, Suh DJ. Which responsecriteria best help predict survival of patients with hepatocellular carcinomafollowing chemoembolization? A validation study of old and newmodels. Radiology 2012;262:708-18.
9. Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, Iwaisako K, Ikai I, Uemoto S. Fluorine-18 fluorodeoxyglucose positron emission tomographypredicts tumor differentiation, P-glycoprotein expression, and outcome afterresection in hepatocellular carcinoma. Clin Cancer Res 2007;13:427-33.
10. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S, Ochi H. Usefulness of positron emission tomography withfluorine-18-fluorodeoxyglucose for predicting outcome in patients withhepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-80.
11. Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, Suga T, KawashimaH, Togashi K, Seo S, Kitamura K, Takada Y, Uemoto S. FDG PET as aprognostic predictor in the early post-therapeutic evaluation for unresectablehepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-82.
12. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, Lee MC, Lee DS. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation forhepatocellular carcinoma. J Nucl Med 2009;50:682-7.
13. Ahn SG, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, Lee JD, Kim KS. The roleof preoperative [18F]fluorodeoxyglucose positron emission tomography inpredicting early recurrence after curative resection of hepatocellular carcinomas. J Gastrointest Surg 2011;15:2044-52.
14. Lee JD, Yun M, Lee JM, Choi Y, Choi YH, Kim JS, Kim SJ, Kim KS, Yang WI, Park YN, Han KH, Lee WJ, Yoo N, Lim SM, Park JH. Analysis of gene expressionprofiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. EurJ Nucl Med Mol Imaging 2004;31:1621-30.
15. Shin DY, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinomaundergoing systemic treatment, a retrospective cohort study. CancerChemother Pharmacol 2011;68:165-75.
16. Kim JW, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH. Usefulness ofpositron emission tomography with fluorine-18-fluorodeoxyglucose in predictingtreatment response in unresectable hepatocellular carcinoma patientstreated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2012;82:1172-8.
17. Song MJ, Bae SH, Lee SW, Song do S, Kim HY, Yoo Ie R, Choi JI, Lee YJ, ChunHJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumourprogression after transarterial chemoembolization in hepatocellularcarcinoma. Eur J Nucl Med Mol Imaging 2013;40:865-73.
18. Lee JH, Park JY, Kim do Y, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Prognosticvalue of 18F-FDG PET for hepatocellular carcinoma patients treatedwith sorafenib. Liver Int 2011;31:1144-9.
19. Lei Liu, Weijuan Wang, Hui Chen, Yan Zhao, Wei Bai, Zhanxin Yin, ChuangyeHe, Jia Jia, Man Yang, Jielai Xia, Daiming Fan, Guohong Han. EASL- andmRECIST-evaluated responses to combination therapy predict survival in patientswith hepatocellular carcinoma. Clin Cancer Res 2014; accepted.
20. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, MeyerhardtJ, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers ofsunitinib monotherapy in advanced hepatocellular carcinoma: a phase IIstudy. J Clin Oncol 2009;27:3027-35.
21. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascularendothelial growth factor in patients with hepatocellular carcinoma and effectof transcatheter arterial chemoembolization therapy on plasma vascular endothelialgrowth factor level. World J Gastroenterol 2004;10:2878-82.
22. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression ofvascular endothelial growth factor in hepatocellular carcinoma aftertranscatheter arterial chemoembolization. Acta Radiol 2008;49:523-9.
23. Tseng CS, Lo HW, Chen PH, Chuang WL, Juan CC, Ker CG. Clinical significanceof plasma D-dimer levels and serum VEGF levels in patients withhepatocellular carcinoma. Hepatogastroenterology 2004;51:1454-8.
24. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, RashidA, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelialgrowth factor into a new scoring system to stratify patients with advancedhepatocellular carcinoma for clinical trials. Cancer 2011;117:2478-88.